Generic Name
Purixan
FDA approval date: February 13, 2004
Classification: Nucleoside Metabolic Inhibitor
Form: Tablet, Suspension
What is Purixan?
Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment